Per una migliore esperienza, mantieni il tuo browser aggiornato. Controlla qui le ultime versioni.

May 2022

Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclosporine A for Inhalation (L-CsA-i) in Patients with Bronchiolitis Obliterans Syndrome (BOS)

Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people’s health and the quality of patients’ lives, announced that the Company has completed enrollment in its two pivotal Phase 3 studies. The trials are designed to evaluate the safety and efficacy of Liposomal Cyclosporine A for Inhalation (L-CsA-i) for the treatment of BOS in adults following single lung (BOSTON-1) or double lung (BOSTON-2) transplantation. 

BOS is a rapidly progressive inflammatory rare disease that irreversibly destroys the airways of the lungs and usually leads to respiratory failure and death within two to four years after diagnosis. Unfortunately, approximately 50 percent of lung transplant patients develop BOS within five years post-transplant, the highest rejection rate of any transplanted organ. Currently, there is no approved treatment indicated for BOS.

Paola Castellani
Chief medical officer and R&D head at Zambon

The completion of enrollment in our Phase 3 BOSTON-1 and -2 studies represents a significant milestone for Zambon and the patient community we aim to serve. On behalf of the Company, we would like to thank the many participants in our Phase 3 clinical program, as well as our study sites and investigators for their commitment. We look forward to reporting top-line results from the program during 2024. 

L-CsA-i is a novel, inhaled therapy administered via the optimized investigational eFlow® Technology nebulizer system (PARI Pharma GmbH). The BOSTON-1 and -2 studies enrolled a total of 231 patients in Europe, Israel and the United States and had participation from 42 lung transplant centers globally. 
Ilaria Villa
CEO at Zambon

At Zambon, we are committed to advancing new therapeutic options that have the potential to make lives better for people affected by severe respiratory diseases such as BOS. The completion of enrollment in our pivotal trials brings us one step closer to our goal of bringing a much-needed therapy to the lung transplant recipients worldwide with BOS

Zambon is also advancing one additional clinical study, BOSTON-3 – an extension study that is open to eligible participants who complete the BOSTON-1 and-2 studies.

L-CsA-i has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and European Medicines Agency for the treatment of BOS, reflecting the high unmet need of the disease. The Fast Track designation was also granted by FDA. If approved, L-CsA-i would be the first treatment indicated for BOS.

Read the press release
act

News

Scopri la sezione News per restare sempre aggiornato su ciò che riguarda gli zoner e sui temi pià rilevanti legati all'innovazione e alle Scienze della Vita.
tutte le news